journal article·2023-12-31Open access

Design and assembly of a nanoparticle, antibody, phthalocyanine scaffold for intracellular delivery of photosensitizer to human papillomavirus-transformed cancer cells

Elvin Peter Chizenga, Heidi Abrahamse

Abstract

In photodynamic therapy (PDT), internalization and uptake of the photosensitizer (PS) by the cells is a passive process that relies on the enhanced permeability and retention (EPR) effect of tumour tissues due to their vasculature, increased LDL receptors, and decreased lymphatic drainage in vivo. But as worries about PDT resistance grow, using passive techniques to administer PSs is becoming less and less viable. According to reported resistance mechanisms, it is necessary to improve PS delivery by changing PS absorption and bioavailability in order to enhance the therapeutic outcome. Therefore, in this study, a multifunctional photosensitizing agent with specific monoclonal antibodies (mAbs) to E6 oncoproteins was developed for PDT of human papillomavirus (HPV)-transformed cancer cells. Using PEGylated Gold Nanoparticles (PEGy-AuNP) at the core, anti-E6 mAbs and phthalocyanines were bound together. This compound demonstrated enhanced internalization of PS, resulting in enhanced PDT effects. In spite of being demonstrated in vitro, the substance in this work is intended for in vivo application, and conclusions are drawn to suggest possible outcomes for in vivo models based on observed data. By making PSs more bioavailable, facilitating their entry into cells, and preventing efflux through intracellular binding, this strategy may reduce cellular resistance to PDT.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Retinoids in leukemia and cellular processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa

Funding

South African Research Chairs Initiative of the Department of Science and Technology · National Research Foundation of South Africa

References (25)

Show source-provided references
1. 10.3390/ijms2111374210.3390/ijms21113742 ↗
2. 10.1039/c1pp05014a10.1039/c1pp05014a ↗
3. Hudson R · Br J Cancer · 2005 · 92 · 144210.1038/sj.bjc.6602517 ↗
4. Malatesti N · Int J Cancer · 2006 · 28 · 1561
5. 10.2147/IJN.S27909410.2147/IJN.S279094 ↗
6. Di Pasqua AJ · Mater Lett · 2009 · 63 · 187610.1016/j.matlet.2009.05.070 ↗
7. 10.1016/j.sbsr.2016.04.00210.1016/j.sbsr.2016.04.002 ↗
8. Okyem S · Bioconjug Chem · 2021 · 32 · 175310.1021/acs.bioconjchem.1c00261 ↗
9. 10.1021/acsami.6b0509910.1021/acsami.6b05099 ↗
10. 10.1016/j.bbrc.2015.10.06610.1016/j.bbrc.2015.10.066 ↗
11. Alarcón-Segovia D · J Autoimmun · 1996 · 9 · 29510.1006/jaut.1996.0038 ↗
12. Alarcon-Segovia D · J Immunol · 1979 · 122 · 185510.4049/jimmunol.122.5.1855 ↗
13. 10.1038/nrrheum.2016.2310.1038/nrrheum.2016.23 ↗
14. 10.1002/art.3447310.1002/art.34473 ↗
15. Douglas JNGL · J Clin Cell Immunol · 2013 · 4 · 134
16. 10.1016/j.jphotochem.2012.02.01210.1016/j.jphotochem.2012.02.012 ↗
17. 10.1080/17460441.2021.196935910.1080/17460441.2021.1969359 ↗
18. 10.1038/nrc.2017.3610.1038/nrc.2017.36 ↗
19. 10.1385/IR:25:2:09710.1385/IR:25:2:097 ↗
20. Lisi S · J Oral Pathol Med · 2007 · 36 · 51110.1111/j.1600-0714.2007.00563.x ↗
21. 10.1007/s00018-009-9179-210.1007/s00018-009-9179-2 ↗
22. 10.4161/mabs.3638910.4161/mabs.36389 ↗
23. 10.1016/j.biomaterials.2008.11.00710.1016/j.biomaterials.2008.11.007 ↗
24. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
25. 10.1021/mp500439c10.1021/mp500439c ↗